☆ 4.6 Review

PD-1/PD-L1 inhibitors in treatment-naive, advanced non-small cell lung cancer patients with < 1% PD-L1 expression: a meta-analysis of randomized controlled trials

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Frontline anti-PD-1/PD-L1 versus bevacizumab in advanced non-small-cell lung cancer: a network meta-analysis

Jiarui Chen et al.

Summary: For patients with high PD-L1 expression, PD-1 inhibitors combined with platinum-doublet therapy have significant benefits in progression-free survival. For patients with PD-L1 <50%, anti-PD-1/PD-L1 therapy is comparable to bevacizumab. In the liver metastatic population, anti-PD-1 combined with chemotherapy may offer benefits in progression-free survival.

FUTURE ONCOLOGY (2022)

Add to Collection

Article Oncology

Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial

Shengxiang Ren et al.

Summary: This study demonstrates the effectiveness and safety of camrelizumab plus chemotherapy as a first-line treatment for advanced squamous NSCLC, with on-treatment ctDNA dynamics showing potential as a predictor of efficacy.

JOURNAL OF THORACIC ONCOLOGY (2022)

Add to Collection

Article Oncology

Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC

Mark M. Awad et al.

Summary: First-line pembrolizumab plus pemetrexed-carboplatin showed continued improved response and survival compared to chemotherapy alone in advanced nonsquamous NSCLC, with durable clinical benefit in patients who completed 2 years of therapy. No new safety signals were observed with longer follow-up.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Article Oncology

Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial

Makoto Nishio et al.

Summary: The IMpower132 study demonstrated significant improvement in PFS with APP compared to PP, but the difference in OS between the two groups was not statistically significant. APP showed favorable OS and PFS results across subgroups, with a manageable safety profile and no new or unexpected safety signals identified.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Article Critical Care Medicine

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial

Caicun Zhou et al.

Summary: The study showed a statistically significant and clinically meaningful improvement in progression-free survival with camrelizumab plus chemotherapy compared to chemotherapy alone, making it a promising first-line treatment option for Chinese patients with advanced non-squamous NSCLC without EGFR and ALK alterations, with further long-term outcomes and confirmatory testing still ongoing.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection

Article Oncology

Non-Small Cell Lung Cancer, Version 2.2021 Featured Updates to the NCCN Guidelines

David S. Ettinger et al.

Summary: The NCCN Guidelines for NSCLC cover all aspects of management, with recent updates focusing on targeted therapies, immunotherapies, and their respective biomarkers.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

Add to Collection

Article Medicine, General & Internal

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Ahmet Sezer et al.

LANCET (2021)

Add to Collection

Article Oncology

Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189

D. Rodriguez-Abreu et al.

Summary: Pembrolizumab plus pemetrexed-platinum continues to demonstrate improved efficacy outcomes compared to placebo plus pemetrexed-platinum, with manageable toxicity, supporting its first-line use in previously untreated metastatic nonsquamous non-small-cell lung cancer patients.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer

Hui Yu et al.

Summary: This study conducted an indirect comparison between ICI + chemo and beva + chemo in first-line treatment for non-squamous NSCLC. The results showed that ICI + chemo reduced the risk of disease progression and death compared with beva + chemo. Overall, ICI + chemo was found to be superior to beva + chemo in this setting.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Review Oncology

Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis

Ling Peng et al.

Summary: The network meta-analysis of frontline treatment options for ALK-positive NSCLC included 9 RCTs with 2,484 patients. Lorlatinib showed the highest PFS benefit and lowest risk of CNS progression, but also higher toxicity. The use of newer generation ALK-TKIs in first-line treatment for ALK-positive NSCLC is rapidly evolving in current clinical practice.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Review Medicine, General & Internal

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Matthew J. Page et al.

Summary: The PRISMA statement was designed to help systematic reviewers transparently report the purpose, methods, and findings of their reviews. The updated PRISMA 2020 statement includes new reporting guidance, a 27-item checklist, an abstract checklist, and revised flow diagrams for reviews.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Oncology

Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer A Phase 3 Randomized Clinical Trial

Jie Wang et al.

Summary: This study showed that tislelizumab combined with chemotherapy can significantly improve progression-free survival in patients with advanced squamous non-small-cell lung cancer, providing potential benefits in clinical practice.

JAMA ONCOLOGY (2021)

Add to Collection

Article Oncology

Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy

Marta Casarrubios et al.

Summary: The study aimed to characterize the T-cell receptor (TCR) repertoire as a potential predictive biomarker for pathologic response to immunotherapy in locally advanced nonsmall cell lung cancer (NSCLC). The analysis revealed a positive association between an uneven TCR repertoire in tissue samples and complete pathologic response (CPR) after surgery. Furthermore, top 1% TCR clones in diagnostic biopsies showed potential as predictive biomarkers for CPR, outperforming PD-L1 tumor proportion score (TPS) and tumor mutational burden (TMB).

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Oncology

Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study

Yunpeng Yang et al.

Summary: This study showed that the addition of sintilimab to chemotherapy significantly prolonged overall survival in nonsquamous NSCLC patients. High expression of the MHC class II antigen presentation pathway could identify patients who benefit most from this combination treatment.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Article Oncology

Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial

Shun Lu et al.

Summary: The addition of tislelizumab to chemotherapy in patients with advanced nonsquamous NSCLC resulted in significantly prolonged progression-free survival (PFS), higher response rates, and longer response duration compared with chemotherapy alone, indicating a promising new option for first-line treatment regardless of disease stage.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Article Oncology

Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)

Caicun Zhou et al.

Summary: A randomized, double-blind, phase 3 study found that Sintilimab plus GP showed better progression-free survival compared to GP alone in first-line treatment for patients with locally advanced or metastatic sqNSCLC. The toxicity of the treatment was acceptable, and no new unexpected safety signals were observed.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Review Oncology

Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC

Michael J. Grant et al.

Summary: The treatment landscape of driver-negative non-small-cell lung cancer is rapidly changing due to the efficacy of immune-checkpoint inhibitors targeting PD-1 or PD-L1 as first-line therapy. Histological subtype and PD-L1 expression levels are crucial factors in regimen selection for patients, with emerging biomarkers and novel strategies potentially refining treatment paradigms in the future. Immune-checkpoint inhibitors are now standard-of-care therapies for patients with advanced-stage NSCLC, with various approved regimens available, highlighting the need for further research to optimize outcomes.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

Robert Jotte et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

Add to Collection

Article Oncology

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

Neal Ready et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

Howard West et al.

LANCET ONCOLOGY (2019)

Add to Collection

Review Psychiatry

A systematic review and meta-analysis of clinical predictors of lithium response in bipolar disorder

T. P. Hui et al.

ACTA PSYCHIATRICA SCANDINAVICA (2019)

Add to Collection

Review Oncology

Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?

P. Hofman et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Review Oncology

Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis

Steve Lu et al.

JAMA ONCOLOGY (2019)

Add to Collection

Article Oncology

The association of PD-L1 expression with the efficacy of antiPD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials

Yangyang Xu et al.

TRANSLATIONAL LUNG CANCER RESEARCH (2019)

Add to Collection

Article Oncology

Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations That Can Be Used for Monitoring Response to Immunotherapy in Cancer Patients

Taylor J. Jensen et al.

MOLECULAR CANCER THERAPEUTICS (2019)

Add to Collection

Article Oncology

Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer

J. Adam et al.

ANNALS OF ONCOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

M. D. Hellmann et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Review Oncology

Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)

Young Kwang Chae et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer

L. Paz-Ares et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Review Pathology

PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted?

Paul Hofman

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2017)

Add to Collection

Article Medicine, General & Internal

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Achim Rittmeyer et al.

LANCET (2017)

Add to Collection

Article Oncology

Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies

M. Ilie et al.

ANNALS OF ONCOLOGY (2016)

Add to Collection

Article Medical Laboratory Technology

Programmed Death Ligand-1 Immunohistochemistry Friend or Foe?

Keith M. Kerr et al.

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)

Add to Collection

Review Oncology

Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?

Young Kwang Chae et al.

CLINICAL LUNG CANCER (2016)

Add to Collection

Review Pathology

Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients

Marius Ilie et al.

VIRCHOWS ARCHIV (2016)

Add to Collection

Article Anatomy & Morphology

Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer

Charlotte Roach et al.

APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2016)

Add to Collection

Article Oncology

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer

Joseph McLaughlin et al.

JAMA ONCOLOGY (2016)

Add to Collection

Article Medicine, Research & Experimental

Meta-analysis of individual patient data versus aggregate data from longitudinal clinical trials

Ashley P. Jones et al.

CLINICAL TRIALS (2009)

Add to Collection

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

Add to Collection

Article Public, Environmental & Occupational Health

Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation

Nikolaos A. Patsopoulos et al.

INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2008)

Add to Collection

Article Oncology

Individual patient-level and study-level meta-analysis for investigating modifiers of treatment effect

S Teramukai et al.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2004)

Add to Collection

Article Medicine, General & Internal

Measuring inconsistency in meta-analyses

JPT Higgins et al.

BMJ-BRITISH MEDICAL JOURNAL (2003)

Add to Collection

Article Health Care Sciences & Services

A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis

PC Lambert et al.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2002)

Add to Collection

Article Health Care Sciences & Services

Funnel plots for detecting bias in meta-analysis: Guidelines on choice of axis

JAC Sterne et al.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2001)

Add to Collection

Article Biology

Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis

S Duval et al.

BIOMETRICS (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.